AstraZeneca (LON:AZN) Stock Crosses Above 200-Day Moving Average – Time to Sell?

Shares of AstraZeneca PLC (LON:AZN) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of £117.76 and traded as high as £136.88. AstraZeneca shares last traded at £135.96, with a volume of 558,747,313 shares traded.

Analyst Ratings Changes

AZN has been the topic of several research analyst reports. Jefferies Financial Group reissued a “buy” rating and set a £150 target price on shares of AstraZeneca in a research report on Monday, November 10th. JPMorgan Chase & Co. reissued an “overweight” rating and set a £140 price objective on shares of AstraZeneca in a report on Thursday, December 4th. Shore Capital restated a “buy” rating and issued a £145 target price on shares of AstraZeneca in a research note on Thursday, November 6th. Finally, Berenberg Bank boosted their price target on AstraZeneca from £142 to £145 and gave the company a “buy” rating in a research note on Tuesday, October 21st. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of £138.

AstraZeneca Stock Performance

The firm’s fifty day simple moving average is £131.40 and its 200 day simple moving average is £117.97. The company has a market capitalization of £208.42 billion, a PE ratio of 22.33, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.